Liquid Biopsy Cancer Testing
Working Group Charter
Clinical Implementation of Multimodal Liquid Biopsy Cancer Testing
Work Product Category
Manuscript or Publication
Specific Aims for the Work Product
Review current practices and guidelines for multimodal liquid biopsy cancer testing.
Recommend best practices for implementation of clinical testing by surveying experts.
Describe the breadth and depth of liquid biopsy testing and seek to improve harmonization across labs.
The working group aims to write a manuscript that overviews current practices and
guidelines for multimodal liquid biopsy cancer testing. We plan to cover each step of the testing process, including preanalytic variables, multimodal sequencing (gene mutations, copy number variants, methylation, fragmentomics), computational analysis, and interpretation. Clinical application and validation varies for use cases, including detection, monitoring MRD, treatment. We aim to describe the breadth and depth of liquid biopsy testing and will seek to improve harmonization across labs. We will describe limitations of the field and recommend best practices for implementation of clinical testing by surveying experts.
Working Group Members
Alyssa Parker
Vanderbilt University
Shiva Sathyanarayana
Dartmouth-Hitchcock Medical Center
Qiliang (Andy) Ding
Mayo Clinic
Bryan Iorgulescu
MD Anderson Cancer Center
Jianling Ji
Children's Hospital Los Angeles
Zejuan Li
Houston Methodist Hospital
Mohamed Maher
MD Anserson Cancer Center
Trevor Pugh
Princess Margaret Cancer Centre
Trevor Pugh
Princess Margaret Cancer Centre